Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve ...
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
(Alliance News) - AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow this month to hopes for the product. Datopotamab deruxtecan, also ...
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...
London stocks were set to rise at the open on Monday following heavy losses at the end of last week. The FTSE 100 was called ...